Jae Hyung Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jae Hyung Park has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Dong Woo Son
Department of Biochemistry Yonsei University Seoul Republic of Korea
12 shared publications - Dongkyu Jeon
College of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Korea
12 shared publications - Han-Sol Jeong
School of Korean Medicine, Pusan National University, Yangsan 50612, Republic of Korea
12 shared publications - Han-Woong Lee
Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University
12 shared publications - Heon Yung Gee
Department of Pharmacology, Brain Korea 21 PLUS Project for Medical Sciences, Yonsei University College of Medicine, Seoul, Republic of Korea
12 shared publications - Hocheol Lim
Bioinformatics and Molecular Design Research Center (BMDRC), Incheon, Republic of Korea
12 shared publications
Latest Publications
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs
Glucose availability affects the anticancer potential of non-oncology drugs in vivo
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs
Glucose availability affects the anticancer potential of non-oncology drugs in vivo
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs
Signaling pathway perturbation in response to biguanide/low glucose treatment in various cancer types
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs
Signaling pathway perturbation in response to biguanide/low glucose treatment in various cancer types
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs
Glutamine availability affects the anticancer potential of non-oncology drugs
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs
Glutamine availability affects the anticancer potential of non-oncology drugs
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs
Validation of CM-SLP using anti-arrhythmic drugs included in CM-SLP
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs
Validation of CM-SLP using anti-arrhythmic drugs included in CM-SLP
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs
Redirecting metabolic interventions toward TEAD targeted therapy improves the clinical applicability of CM-SLP
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs
Redirecting metabolic interventions toward TEAD targeted therapy improves the clinical applicability of CM-SLP
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs
The voltage-gated potassium channel inhibitor PAP-1, which lacks anticancer efficacy, does not target the mTOR pathway or Kca channels
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs
The voltage-gated potassium channel inhibitor PAP-1, which lacks anticancer efficacy, does not target the mTOR pathway or Kca channels
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs
Table S3 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs
Table S3 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs
Table S1 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs
Table S1 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs
Anticancer effects of propafenone are not mediated via its canonical targets
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs
Anticancer effects of propafenone are not mediated via its canonical targets
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs
Table S2 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs
Table S2 from Nutrient Availability Dictates Cancer Metabolism–Based Therapeutic Responses to Nononcology Drugs